Ligelizumab

Ligelizumab is a monoclonal antibody designed for the treatment of chronic spontaneous urticaria (CSU). It is developed by Novartis, a Swiss multinational pharmaceutical company. Ligelizumab works by targeting and neutralizing immunoglobulin E (IgE), a type of antibody that plays a key role in allergic reactions.

Mechanism of Action

Ligelizumab is a monoclonal antibody that binds to IgE, preventing it from attaching to mast cells and basophils. This inhibits the release of inflammatory mediators like histamine, which are responsible for the symptoms of CSU.

Clinical Trials

Ligelizumab has undergone several clinical trials to evaluate its safety and efficacy. In a Phase IIb study, ligelizumab demonstrated superior efficacy compared to omalizumab, another IgE inhibitor, in patients with CSU who were unresponsive to antihistamines.

Approval

As of 2021, ligelizumab is not yet approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). However, it is under review by these regulatory bodies.

See Also

• Monoclonal antibodies
• Chronic spontaneous urticaria
• Immunoglobulin E
• Novartis

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

   This article is a medical stub. You can help WikiMD by expanding it!